You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Indications

Active ingredients of Anoro Ellipta1

Anoro Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) inhalation powder

Each single inhalation of umeclidinium bromide (UMEC) 62.5 micrograms (mcg) and vilanterol (VI) 25mcg provides a delivered dose of UMEC 55mcg and VI 22mcg.

COPD

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).1

Innoviva logo

Reference:

  1. Anoro Ellipta 52/22 mcg SPC; GlaxoSmithKline 2018

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies